• Explore /
  • Poster
  • / Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Abstract Video & Slides Poster

Authors

null

Susana N. Banerjee

The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI), London, United Kingdom

Susana N. Banerjee , Kari Lassen Ring , Els Van Nieuwenhuysen , Michel Fabbro , Carol Aghajanian , Ana Oaknin , Nicoletta Colombo , Alessandro Santin , Andrew R. Clamp , Kathleen N. Moore , Peter Graham Rose , David M. O'Malley , Hye Sook Chon , Erin A Salinas , Emily N Prendergast , Stephanie Lustgarten , Manuel Rodrigues , Christine Gennigens , Bradley J. Monk , Rachel N. Grisham

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT04625270

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5515)

DOI

10.1200/JCO.2023.41.16_suppl.5515

Abstract #

5515

Poster Bd #

210

Abstract Disclosures

Similar Posters

First Author: Susana N. Banerjee

First Author: Susana N. Banerjee

First Author: Bradley J. Monk

First Author: Joshua E. Reuss